Kurtz, David M <br/><br/>
Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51.  [electronic resource] 

 -  Leukemia & lymphoma  Jul 2007 
 - 1290-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1042-8194 
<br/><br/><label>Standard No.: </label>10.1080/10428190701355028  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Interleukin-4--administration & dosage<br/>Lymphoma, Non-Hodgkin--complications<br/>Male<br/>Middle Aged<br/>Recurrence<br/>Salvage Therapy--methods<br/>Survival Analysis<br/>Treatment Outcome